Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2023) 90 EP968 | DOI: 10.1530/endoabs.90.EP968

ECE2023 Eposter Presentations Thyroid (128 abstracts)

Benign and Malignant Thyroglossal Duct Cyst Remnants: Systematic Review and Case Series of 1842 Surgical Cases

Ioannis Zoupas 1 , Juan C Jaume 2 , Sarantis Livadas 3,4 , Evaggelos Karvounis 5 , Dimitra Bantouna 6 , Shanawaz Imam 2 & Rodis Paparodis 7,8


1National and Kapodistrian University of Athens, Medical School, Athens, Greece; 2University of Toledo College of Medicine and Life Sciences, Center for Diabetes and Endocrine Research, Toledo, OH, United States; 3Athens Medical Center, Endocrinology, Diabetes and Metabolism, Athens, Greece; 4Endocrinology, Diabetes and Metabolism Clinics, Private Practice, Athens, Greece; 5Euroclinic Hospital, Endocrine Surgery Center of Excellence, Athens, Greece; 6Private Practice, Patras, Greece; 7University of Toledo College of Medicine and Life Sciences, Center for Diabetes and Endocrine Research, Patras, Greece; 8Endocrinology, Diabetes and Metabolism Clinics, Private Practice, Patras, Greece


Introduction: Thyroglossal duct (TGD) carcinoma is an uncommon entity, diagnosed in patients undergoing evaluation of the neck for midline swelling, or incidentally after removal of a TGD cyst. Despite the presence of multiple publications on the topic, no systematic characterization of these tumors has been performed to date.

Methods: We performed a systematic search for the term “Thyroglossal duct” in Pubmed, Embase and Cochrane databases on December 1, 2021 and retrieved 1229 records. We excluded articles other than case reports or case series, and those written in languages other than English, Italian, French or Spanish.

Results: We incorporated data from 366 manuscripts, comprising 1202 patients operated for TGD disease. Out of these, n=550 cancers were identified, consisting of n=475 (86.4%) Papillary carcinomas (PTC), n=8 Follicular carcinomas (FTC) (1.5%), n=5 Hürthle cell carcinomas (HCC) (0.9%), n=27 Squamous cell carcinomas (SCC) (4.9%), n=2 poorly differentiated/anaplastic thyroid carcinomas (ATC) (0.4%), n=1 Adeno-SCC (0.18%), n=1 Adenocarcinoma (0.18%), n=12 synchronous PTC/FTC (2.2%), n=1 synchronous PTC/SCC (0.18%) and n=18 of unclear histological diagnosis (4.75%). n=173 patients were males and n=273 were females; gender was not available in n=104 cases. Mean cancer size was 1.3±1.3 cm (range 0.01-7.0 cm); 49.6% were microcarcinomas (<1 cm). Lymph node involvement was present in n=62/243 (25.3%). Distant metastasis was present in n=4 patients (0.7%).

Conclusions: TGD remnant cancers include various tumors, with histology and features of aggressive behavior similar to what we see in thyroid cancer cases. More research is needed to better understand the mechanisms of tumorigenesis in the TGD.

Volume 90

25th European Congress of Endocrinology

Istanbul, Turkey
13 May 2023 - 16 May 2023

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.